Sanofi's Tzield Approved in the US to Delay the Onset of Stage 3 Type 1 Diabetes in Young Children
April 23, 2026
April 23, 2026
PARIS, France, April 23 (TNSrep) -- Sanofi, a life sciences company, issued the following news release:
* * *
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
* Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3
* Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D
. . .
* * *
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
* Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3
* Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D
. . .